Teniposide 50 mg/5 mL (10 mg/mL vial) Suppliers & Bulk Manufacturers

Available Forms: Injection (IV)

Available Strengths: 50 mg/5 mL (10 mg/mL vial)

Reference Brands: Vumon® (EU & US)

Category: Oncology Cancer Care

Teniposide is a topoisomerase II inhibitor used in oncology, primarily for treating acute lymphoblastic leukemia (ALL) in pediatric patients. Marketed under the brand name Vumon®, it is available in 50 mg/5 mL (10 mg/mL) IV vials in both the US and EU. Teniposide is a critical component in combination chemotherapy protocols and is supplied under GMP-compliant manufacturing. Ideal for pharma B2B partners, Teniposide supports trusted oncology supply chains across regulated markets.

Product Description: Teniposide Injection is a potent chemotherapeutic agent used in the treatment of acute lymphoblastic leukemia (ALL), especially in pediatric patients with relapsed or refractory disease. Classified as a topoisomerase II inhibitor, Teniposide disrupts DNA replication and cell division, making it effective in oncology protocols. It is commercially available in the US and EU under the brand name Vumon®, typically in 50 mg/5 mL (10 mg/mL) injectable vials. Teniposide is manufactured under strict GMP standards, making it ideal for B2B pharmaceutical distributors, hospital tenders, and global supply chains seeking reliable oncology solutions in regulated markets.